Dostarlimab Elicits Survival Benefit in dMMR/MSI-H Advanced Endometrial Cancer
October 11th 2022Single-agent dostarlimab-gxly produced progression-free survival and overall survival benefits in patients with advanced or recurrent mismatch repair–deficient/microsatellite instability–high endometrial cancer.
Read More
Frontline Avelumab Maintenance Displays Long-Term Benefit in Advanced Urothelial Carcinoma
October 10th 2022Jeanny B. Aragon-Ching, MD, FACP, discusses the results of the subgroup analysis in patients with urothelial carcinoma who received frontline avelumab maintenance for at least 12 months on the phase 3 JAVELIN Bladder 100 trial.
Read More
Gilteritinib Induces Encouraging Responses in Newly Diagnosed FLT3-Mutated AML
October 9th 2022Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.
Read More
Neoadjuvant Radioimmunotherapy Demonstrates Feasibility in Locally Advanced Urothelial Carcinoma
October 7th 2022Sebastian C. Schmid, MD, discusses the results of the RACE IT trial, what the data mean for patients with locally advanced urothelial carcinoma, and the next steps for researching neoadjuvant radioimmunotherapy in this patient population.
Read More
Durvalumab, Tremelimumab, and Chemotherapy Elicit Promising Long-Term OS Rates in NSCLC
October 6th 2022Melissa L. Johnson, MD, expands on the updated data from the POSEIDEN trial, the rationale for investigating the combination, and what these results mean for the treatment of metastatic non–small cell lung cancer.
Read More
Patient-Reported Outcomes Support Use of Trastuzumab Deruxtecan in HR+/HER2-Negative Breast Cancer
October 6th 2022Fam-trastuzumab deruxtecan-nxki preserved quality of life vs physicians choice of treatment in patients with advanced, hormone receptor–positive/HER2-low metastatic breast cancer.
Read More
Loncastuximab Tesirine/Rituximab Elicits Promising Anti-Tumor Activity in Relapsed/Refractory DLBCL
October 3rd 2022Loncastuximab tesirine-lpyl combined with rituximab demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Sunvozertinib Generates Responses in Platinum-Pretreated EGFR Exon 20–Mutated NSCLC
September 27th 2022Sunvozertinib provided beneficial antitumor activity when used as a second- or later-line treatment in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy.
Read More
Fruquintinib Provides Significant Survival Benefits in Heavily Pretreated mCRC
September 26th 2022Nageshwara Arvind Dasari, MD, discusses the results of the phase 3 FRESCO-2 trial of fruquintinib in patients with refractory metastatic colorectal cancer, the significance of the data for the treatment paradigm, and the potential next steps for examining the agent in this disease.
Read More
Frontline Immunotherapy Combos Linked With Higher CR Rates Than Anti-VEGF Therapy in mRCC
September 20th 2022Immunotherapy-based combinations elicited higher complete response rates compared with VEGF-targeted therapy when used as first-line treatment in patients with metastatic renal cell carcinoma.
Read More
Surgical Complications Unrelated to Timing of Neoadjuvant Chemotherapy in Lower-Extremity Sarcomas
September 6th 2022R. Lor Randall, MD, FACS, discusses the findings from a subset analysis of the PARITY trial on the timing of neoadjuvant chemotherapy in patients with lower-extremity sarcomas.
Read More
Social Determinants and Genetics Work in Tandem to Drive Disparities in Breast Cancer Care
September 2nd 2022Adana A.M. Llanos, PhD, MPH, discusses key research on the social and biological factors that influence disparities in breast cancer, how these factors work in tandem to affect patient outcomes, and how this knowledge can be deployed in the real world.
Read More
Fixed-Duration Glofitamab Elicits Early, Durable Complete Remissions in Relapsed/Refractory LBCL
September 2nd 2022Michael Dickinson, MBBS, expands on data from a phase 2 dose-expansion study of glofitamab in heavily pretreated, highly refractory large B-cell lymphoma, explains the effect bispecific antibodies could have on treatment, and highlights other research efforts surrounding glofitamab-based therapies.
Read More
SEL24/MEN1703 Demonstrates Early Efficacy, Tolerability in R/R AML With IDH1/2 Mutations
September 1st 2022The first-in-class dual PIM/FLT3 kinase inhibitor, SEL24/MEN1703, showcased encouraging efficacy and a tolerable safety profile in patients with acute myeloid leukemia whose tumors harbor a IDH1/2 mutation.
Read More
Single-Agent Belantamab Mafodotin Elicits Activity in Heavily Pretreated Patients With R/R Myeloma
September 1st 2022Belantamab mafodotin monotherapy demonstrated anticancer activity with a tolerable safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma.
Read More
Continued Emergence of Targeted Therapies Reinforces Need for Frequent Genetic Testing in NSCLC
August 25th 2022Although the efficacy of targeted agents and outcomes for patients with genetic mutations can vary, the availability of these treatments adds to the need for genetic testing across all patients with non–small cell lung cancer.
Read More
Acalabrutinib With or Without Obinutuzumab Maintains Long-Term Survival Benefit in Untreated CLL
August 24th 2022Jeff P. Sharman, MD, discusses the meaning of the long-term follow-up data from ELEVATE-TN, the efficacy of acalabrutinib regimens in patients with treatment-naïve chronic lymphocytic leukemia with deletion 17p or TP53 mutations, and factors to consider when adding obinutuzumab to acalabrutinib.
Read More
Relma-cel Demonstrates Durable Activity in Relapsed/Refractory LBCL
August 22nd 2022Relmacabtagene autoleucel elicited durable responses and a high overall survival rate in Chinese patients with relapsed/refractory large B-cell lymphoma, according to 2-year follow-up data from the phase 2 RELIANCE trial.
Read More
CART-ddBCMA Generates Deep Responses in Relapsed/Refractory Multiple Myeloma
August 19th 2022Matthew J. Frigault, MD, discusses the findings from a phase 1 trial investigating the safety and efficacy of CART-ddBCMA in patients with multiple myeloma in whom all previous lines of treatment had failed and shares additional research opportunities for the CAR T-cell therapy.
Read More